Melatonin: A regulator of the interplay between <scp>FoxO1</scp>, <scp>miR96,</scp> and <scp>miR215</scp> signaling to diminish the growth, survival, and metastasis of murine adenocarcinoma

Oshiba, Rehab T.; Touson, Ehab; Elsherbini, Yasser; Abdraboh, Mohamed E.

doi:10.1002/biof.1758

Cited by 9 publications

(6 citation statements)

References 54 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor growth tissues showed positive expression for survivin, while non-tumor tissues displayed little noticeable staining by immunohistochemistry [ 40 ]. Melatonin downregulated the expression of survivin to prevent cell growth, survival, and metastasis of solid tumors [ 61 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Synthesized Indoloquinoline Analog to Isolates from Cryptolepis sanguinolenta on Tumor Growth Inhibition and Hepatotoxicity in Ehrlich Solid Tumor-Bearing Female Mice

Nofal

Elmongy

Hassan

et al. 2023

Cells

View full text Add to dashboard Cite

The study evaluated the antitumor efficacy of APAN, “synthesized indoloquinoline analog derived from the parent neocryptolepine isolated from the roots of Cryptolepis sanguinolenta”, versus the chemotherapeutic drug etoposide (ETO) in Ehrlich solid tumor (EST)-bearing female mice as well as its protective effect against etoposide-triggered hepatic disorders. APAN showed an ameliorative activity against Ehrlich solid tumor and hepatic toxicity, and the greatest improvement was found in the combined treatment of APAN with ETO. The results indicated that EST altered the levels of tumor markers (AFP, CEA, and anti-dsDNA) and liver biomarker function (ALT, AST, ALP, ALB, and T. protein). Furthermore, EST elevated CD68 and anti-survivin proteins immuno-expressions in the solid tumor and liver tissue. Molecular docking studies were demonstrated to investigate their affinity for both TNF-α and topoisomerase II as target proteins, as etoposide is based on the inhibition of topoisomerase II, and TNF-α is quite highly expressed in the solid tumor and liver tissues of EST-bearing animals, which prompted the authors’ interest to explore APAN affinity to its binding site. Treatment of mice bearing EST with APAN and ETO nearly regularized serum levels of the altered parameters and ameliorated the impact of EST on the tissue structure of the liver better than that by treatment with each of them separately.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Synthesized Indoloquinoline Analog to Isolates from Cryptolepis sanguinolenta on Tumor Growth Inhibition and Hepatotoxicity in Ehrlich Solid Tumor-Bearing Female Mice

Nofal

Elmongy

Hassan

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…1 B) is a pineal gland hormone regulating the sleep–wake cycle, gonadal activity, redox homeostasis, and immune functions 12 . It also has anti-tumor properties in different types of cancer, including breast, colorectal, pancreatic, endometrial, kidney, skin, and others 13 – 19 . Of note, melatonin lowers estrogen receptor expression, inhibits DNA replication, prevents metastasis, regulates angiogenesis, and apoptosis 20 , 21 .…”

Section: Introductionmentioning

confidence: 99%

Codelivery of resveratrol melatonin utilizing pH responsive sericin based nanocarriers inhibits the proliferation of breast cancer cell line at the different pH

Aghaz

Asadi

Sajadimajd

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Protein-based nanocarriers have demonstrated good potential for cancer drug delivery. Silk sericin nano-particle is arguably one of the best in this field. In this study, we developed a surface charge reversal sericin-based nanocarrier to co-deliver resveratrol and melatonin (MR-SNC) to MCF-7 breast cancer cells as combination therapy. MR-SNC was fabricated with various sericin concentrations via flash-nanoprecipitation as a simple and reproducible method without complicated equipment. The nanoparticles were subsequently characterized for their size, charge, morphology and shape by dynamic light scattering (DLS) and scanning electron microscope (SEM). Nanocarriers chemical and conformational analysis were done by fourier transform infrared spectroscopy (FT-IR) and circular dichroism (CD) respectively. In vitro drug release was determined at different pH values (7.45, 6.5 and 6). The cellular uptake and cytotoxicity were studies using breast cancer MCF-7 cells. MR-SNC fabricated with the lowest sericin concentration (0.1%), showed a desirable 127 nm size, with a net negative charge at physiological pH. Sericin structure was preserved entirely in the form of nano-particles. Among the three pH values we applied, the maximum in vitro drug release was at pH 6, 6.5, and 7.4, respectively. This pH dependency showed the charge reversal property of our smart nanocarrier via changing the surface charge from negative to positive in mildly acidic pH, destructing the electrostatic interactions between sericin surface amino acids. Cell viability studies demonstrated the significant toxicity of MR-SNC in MCF-7 cells at all pH values after 48 h, suggesting a synergistic effect of combination therapy with the two antioxidants. The efficient cellular uptake of MR-SNC, DNA fragmentation and chromatin condensation was found at pH 6. Nutshell, our result indicated proficient release of the entrapped drug combination from MR-SNC in an acidic environment leading to cell apoptosis. This work introduces a smart pH-responsive nano-platform for anti-breast cancer drug delivery.

show abstract

“…An in vivo study demonstrated that, in adenocarcinoma, melatonin exerted abilities of regulating the interplay between forkhead box protein O1 (FoxO1), miR96, and miR215 signaling. This signaling axis may be a novel target for melatonin to diminish cancer cell growth, survival, and metastasis [ 49 ]. Melatonin can upregulate miRNA-34a/449a to promote apoptosis in colorectal cancer cells and a xenograft mouse model as well [ 50 ].…”

Section: Anticancer Effect Of Melatoninmentioning

confidence: 99%

Use of Melatonin in Cancer Treatment: Where Are We?

Wang

Choi

2022

IJMS

View full text Add to dashboard Cite

Cancer represents a large group of diseases accounting for nearly 10 million deaths each year. Various treatment strategies, including surgical resection combined with chemotherapy, radiotherapy, and immunotherapy, have been applied for cancer treatment. However, the outcomes remain largely unsatisfying. Melatonin, as an endogenous hormone, is associated with the circadian rhythm moderation. Many physiological functions of melatonin besides sleep–wake cycle control have been identified, such as antioxidant, immunomodulation, and anti-inflammation. In recent years, an increasing number of studies have described the anticancer effects of melatonin. This has drawn our attention to the potential usage of melatonin for cancer treatment in the clinical setting, although huge obstacles still exist before its wide clinical administration is accepted. The exact mechanisms behind its anticancer effects remain unclear, and the specific characters impede its in vivo investigation. In this review, we will summarize the latest advances in melatonin studies, including its chemical properties, the possible mechanisms for its anticancer effects, and the ongoing clinical trails. Importantly, challenges for the clinical application of melatonin will be discussed, accompanied with our perspectives on its future development. Finally, obstacles and perspectives of using melatonin for cancer treatment will be proposed. The present article will provide a comprehensive foundation for applying melatonin as a preventive and therapeutic agent for cancer treatment.

show abstract

Melatonin: A regulator of the interplay between FoxO1, miR96, and miR215 signaling to diminish the growth, survival, and metastasis of murine adenocarcinoma

Cited by 9 publications

References 54 publications

Impact of Synthesized Indoloquinoline Analog to Isolates from Cryptolepis sanguinolenta on Tumor Growth Inhibition and Hepatotoxicity in Ehrlich Solid Tumor-Bearing Female Mice

Impact of Synthesized Indoloquinoline Analog to Isolates from Cryptolepis sanguinolenta on Tumor Growth Inhibition and Hepatotoxicity in Ehrlich Solid Tumor-Bearing Female Mice

Codelivery of resveratrol melatonin utilizing pH responsive sericin based nanocarriers inhibits the proliferation of breast cancer cell line at the different pH

Use of Melatonin in Cancer Treatment: Where Are We?

Contact Info

Product

Resources

About